215 related articles for article (PubMed ID: 15145695)
1. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S
J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW
J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro.
Farivar-Mohseni H; Kandzari SJ; Zaslau S; Riggs DR; Jackson BJ; McFadden DW
Am J Surg; 2004 Nov; 188(5):505-10. PubMed ID: 15546559
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
5. COX-2 inhibition and cancer: experimental findings and clinical correlates.
Roberts EG; Vona-Davis L; Riggs DR; Jackson BJ; Hohseni H; Kandzari SJ; McFadden DW
W V Med J; 2004; 100(3):96-101. PubMed ID: 15384741
[TBL] [Abstract][Full Text] [Related]
6. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
[TBL] [Abstract][Full Text] [Related]
8. The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells.
Grossman EM; Longo WE; Panesar N; Mazuski JE; Kaminski DL
Carcinogenesis; 2000 Jul; 21(7):1403-9. PubMed ID: 10874020
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
10. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
Minter HA; Eveson JW; Huntley S; Elder DJ; Hague A
Clin Cancer Res; 2003 May; 9(5):1885-97. PubMed ID: 12738747
[TBL] [Abstract][Full Text] [Related]
11. The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
Yoshimura R; Matsuyama M; Kawahito Y; Takemoto Y; Tsuchida K; Kuratsukuri K; Segawa Y; Shinnka T; Sano H; Nakatani T
Int J Mol Med; 2004 Jun; 13(6):789-93. PubMed ID: 15138613
[TBL] [Abstract][Full Text] [Related]
12. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
Buecher B; Bouancheau D; Broquet A; Bezieau S; Denis MG; Bonnet C; Heymann MF; Jarry A; Galmiche JP; Blottière HM
Anticancer Res; 2005; 25(1A):225-33. PubMed ID: 15816542
[TBL] [Abstract][Full Text] [Related]
15. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.
Kase S; Osaki M; Honjo S; Takeda A; Adachi K; Araki K; Ito H
J Exp Clin Cancer Res; 2004 Jun; 23(2):301-7. PubMed ID: 15354416
[TBL] [Abstract][Full Text] [Related]
16. Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells.
Bottone FG; Martinez JM; Alston-Mills B; Eling TE
Carcinogenesis; 2004 Mar; 25(3):349-57. PubMed ID: 14633654
[TBL] [Abstract][Full Text] [Related]
17. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest.
Cheong E; Ivory K; Doleman J; Parker ML; Rhodes M; Johnson IT
Carcinogenesis; 2004 Oct; 25(10):1945-52. PubMed ID: 15155531
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.
Harel Z
J Pediatr Adolesc Gynecol; 2004 Apr; 17(2):75-9. PubMed ID: 15050982
[TBL] [Abstract][Full Text] [Related]
19. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
Evans JF
Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.
Williams CS; Watson AJ; Sheng H; Helou R; Shao J; DuBois RN
Cancer Res; 2000 Nov; 60(21):6045-51. PubMed ID: 11085526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
